CARLSBAD, Calif. /PRNewswire/
Published October 4, 2023
An excerpt from the original article is posted below:
Aventa™ Genomics, LLC, a clinical laboratory established as a joint venture between Arima Genomics, Inc. and Protean BioDiagnostics Inc., today announced the launch of Aventa FusionPlus, a next-generation sequencing (NGS) test for the detection of gene fusions, translocations, and rearrangements across 361 genes from formalin-fixed, paraffin embedded (FFPE) tumor tissue. Aventa’s testing service is performed in its CLIA-certified laboratory in Orlando, Florida.
“We are happy to make this innovative, clinically impactful, precision laboratory developed diagnostic test available to treating physicians for the benefit of their patients.”